GE HealthCare and Mayo Clinic Launch Theranostics Study for Prostate Cancer

M&A · PartnershipProduct / Tech
โดย Zacks Investment Research·Read original
Summary · why it matters

GE HealthCare and Mayo Clinic have announced a research collaboration to advance personalized cancer treatment through the MI-BET study, which will evaluate whether imaging, blood-based biomarkers, and clinical data can tailor radioligand therapy for patients with advanced prostate cancer. The study will use GE HealthCare's StarGuide SPECT/CT platform and MIM Software's MIM LesionID Pro to monitor tumor response, aiming to determine if data-driven insights can guide decisions such as pausing or adapting therapy. Mayo Clinic has also become the first U.S. site to investigate GE HealthCare's next-generation StarGuide GX SPECT/CT technology, which has CE Mark certification but is not yet approved for commercial sale in the United States. The collaboration is expected to strengthen GE HealthCare's position in the theranostics market, which is projected to grow from $11.50 billion in 2026 to approximately $31.38 billion by 2035. GE HealthCare shares have traded flat since the announcement on July 8 and are down 21.2% year-to-date.

Impact on stocks 4

Biotech & Genomic Medicine▲ · 2 stocks
GE HealthCare Technologies Inc.
GEHC
▲ PositiveTechnologyrelevance

GE HealthCare's StarGuide SPECT/CT platform and next-generation StarGuide GX technology are central to the study, strengthening its theranostics position.

Robotics & Physical AI▲ · 2 stocks

Theme Impact 2

Off-coverage companies 1

MIM Software IncPrivate▲ Positive
Technologyrelevance

MIM Software's MIM LesionID Pro is used in the study to monitor tumor response, highlighting its role in theranostics.

Related news

BioMarin Reports Positive Phase 3 VOXZOGO Hypochondroplasia Data and Files sNDA

BioMarin Pharmaceutical reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug's use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The late-stage data cover an indication with no approved treatments, and the company said the combination of the results and the board appointment underscores its focus on deepening its rare disease franchise and scientific oversight. BioMarin's narrative projects $5.0 billion revenue and $1.3 billion earnings by 2029, requiring 14.0% yearly revenue growth and about a $1.2 billion earnings increase from $73.0 million today, with a $91.42 fair value cited, a 43% upside to its current price. More pessimistic analysts warn that heavy reliance on a few rare disease drugs and uncertainty around future indications could leave BioMarin short of pre-news expectations of about US$4.7 billion in revenue and roughly US$509.5 million in earnings by 2029.
BMRN ▲
Biotech & Genomic Medicine ▲
Simply Wall St·5hRead more →

ChemoMetec Posts Record DKK511 Million Revenue, Guides FY26/27 to DKK545-575 Million

ChemoMetec reported record revenue of DKK511 million for its Q4 2026 fiscal year, up 3% year over year and 7% at constant exchange rates, with EBITDA rising 9% to DKK281 million and the EBITDA margin expanding to 55% from 52.1%. Instrument revenue grew 13% on the strength of XM products including NC-203, whose revenue jumped to DKK68.1 million from DKK27.7 million a year earlier, while the life science business, representing 95% of group revenue, grew 6% to approximately DKK485 million. Consumables revenue fell 4% on the US federal government shutdown in fall 2025, US and Canada revenue slipped 6% in reported terms, and the animal semen, beer and milk business dropped 32% amid a continued market exit. The company repurchased 105,000 shares at year-end for about DKK39 million and roughly 206,600 shares, or 1.2% of share capital, as of the call date, and ended with a cash position of approximately DKK290 million and equity of approximately DKK725 million. For FY2026/27, ChemoMetec guided revenue to DKK545 million to DKK575 million, implying roughly 7% to 13% growth, EBITDA to DKK300 million to DKK330 million, and CapEx to approximately DKK120 million, with CEO Martin Behrens saying the outlook excludes any contribution from the Roche, Tecan and Hamilton collaborations and from delayed XM orders.
0DZ0.LSE
Biotech & Genomic Medicine
GuruFocus·12hRead more →
▲

NAVER D2SF Backs ImpriMed in $10 Million Series A2 Bridge Round

NAVER D2SF, NAVER's in-house corporate venture arm, has invested in Silicon Valley precision medicine company ImpriMed, joining ImpriMed's $10 million Series A2 bridge round. The round was led by LB Investment, with participation from new investors NAVER D2SF, Samsung Securities, and Alois Ventures, plus follow-on investments from existing investors BonAngels and Han River Partners; it follows ImpriMed's $23 million Series A in 2023. ImpriMed combines ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data through its xCellSense platform, and is developing AI models trained on more than 3.5 million data points. The company is preparing to commercialize products for blood cancers and blood infection, targeting FDA clearance and CLIA certification by Q1 2027 for an initial U.S. launch, while in South Korea its multiple myeloma prognosis and therapy-response software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety. ImpriMed was co-founded by CEO Sungwon Lim and CTO Jamin Koo, and its human healthcare expansion is supported by veterinary precision oncology work covering more than 27,000 tests for canine and feline lymphoma, used by over 600 veterinary hospitals across the United States, Canada, the United Kingdom, France, and South Korea.
016360.KO035420.KO1060.HK309960.KOCTO
Biotech & Genomic Medicine ▲
PR Newswire·22hRead more →
© 2026 MarketDXNews